

## Table of content

**Figure S1.** UV-chromatograms of (a) DOTA-MGS5, (b) 1 and (c) 2 after HPLC purification.

**Figure S2.** Mass spectra of (a) DOTA-MGS5, (b) 1 and (c) 2 after HPLC purification.


**Figure S3.** Radiochromatograms of  $^{177}\text{Lu}$ -labeled (a) DOTA-MGS5, (b) 1 and (c) 2: reaction mixture after radiolabeling with minor presence ( $\leq 2\%$ ) of free lutetium-177 (solid line) and after removal of hydrophilic impurities by solid phase extraction (dashed line), respectively.

**Table S1.** Results of biodistribution studies evaluated in A431-CCK2R/A431-mock xenografted BALB/c nude mice of the  $^{177}\text{Lu}$ -labeled peptide derivatives (~0.5 MBq, 20 pmol, 4 h p.i.). Values expressed as percentage of injected activity per gram tissue (% IA/g); mean  $\pm$  SD (n=5).


**Table S2.** Results of the additional biodistribution study with 1000-fold excess of non-radiolabeled peptide (blocking experiment) in A431-CCK2R/A431-mock xenografted BALB/c nude mice of the  $^{177}\text{Lu}$ -labeled peptide derivatives (~0.5 MBq, 20 pmol, 4 h p.i.). Values expressed as percentage of injected activity per gram tissue (% IA/g; n=1).

**Figure S4.** Uptake of  $[^{177}\text{Lu}]\text{Lu-2}$  in different tissues dissected from A431-CCK2R xenografted BALB/c nude mice for up to 7 days after injection (n=5).


**Table S3.** Uptake values of  $[^{177}\text{Lu}]\text{Lu-2}$  in A431-CCK2R tumor xenograft for up to 7 days after injection (n=5).



**Figure S1.** UV-chromatograms of (a) DOTA-MGS5, (b) **1** and (c) **2** after HPLC purification.



**Figure S2.** Mass spectra of (a) DOTA-MGS5, (b) **1** and (c) **2** after HPLC purification




**Figure S3.** Radiochromatograms of  $^{177}\text{Lu}$ -labeled (a) DOTA-MGS5, (b) **1** and (c) **2**: reaction mixture after radiolabeling with minor presence ( $\leq 2\%$ ) of free lutetium-177 (solid line) and after removal of hydrophilic impurities by solid phase extraction (dashed line), respectively.

**Table S1.** Results of biodistribution studies evaluated in A431-CCK2R/A431-mock xenografted BALB/c nude mice of the  $^{177}\text{Lu}$ -labeled peptide derivatives (~0.5 MBq, 20 pmol, 4 h p.i.). Values expressed as percentage of injected activity per gram tissue (% IA/g); mean  $\pm$  SD (n=5).

radiopeptide	[ $^{177}\text{Lu}$ ]Lu-DOTA-MGS5	[ $^{177}\text{Lu}$ ]Lu-1	[ $^{177}\text{Lu}$ ]Lu-2
<b>blood</b>	0.11 $\pm$ 0.11	0.02 $\pm$ 0.00	0.03 $\pm$ 0.01
<b>lung</b>	0.17 $\pm$ 0.14	0.12 $\pm$ 0.04	0.22 $\pm$ 0.06
<b>heart</b>	0.10 $\pm$ 0.06	0.06 $\pm$ 0.01	0.07 $\pm$ 0.02
<b>femur</b>	0.36 $\pm$ 0.35	0.21 $\pm$ 0.05	0.22 $\pm$ 0.15
<b>muscle</b>	0.10 $\pm$ 0.02	0.04 $\pm$ 0.02	0.06 $\pm$ 0.03
<b>spleen</b>	0.27 $\pm$ 0.18	1.86 $\pm$ 0.62	0.96 $\pm$ 0.30
<b>intestine</b>	1.02 $\pm$ 0.23	0.42 $\pm$ 0.07	0.60 $\pm$ 0.12
<b>liver</b>	1.02 $\pm$ 0.80	2.48 $\pm$ 0.39	1.43 $\pm$ 0.18
<b>kidneys</b>	3.45 $\pm$ 0.91	21.60 $\pm$ 2.11	1.96 $\pm$ 0.29
<b>stomach</b>	6.26 $\pm$ 4.28	4.77 $\pm$ 1.10	4.30 $\pm$ 0.95
<b>pancreas</b>	1.91 $\pm$ 0.91	1.25 $\pm$ 0.27	0.72 $\pm$ 0.14
<b>A431-CCK2R</b>	22.8 $\pm$ 4.67	22.18 $\pm$ 6.23	32.10 $\pm$ 4.05
<b>A431-mock</b>	0.19 $\pm$ 0.03	0.14 $\pm$ 0.04	0.22 $\pm$ 0.06

**Table S2.** Results of the additional biodistribution study with 1000-fold excess of non-radiolabeled peptide (blocking experiment) in A431-CCK2R/A431-mock xenografted BALB/c nude mice of the  $^{177}\text{Lu}$ -labeled peptide derivatives (~0.5 MBq, 20 pmol, 4 h p.i.). Values expressed as percentage of injected activity per gram tissue (% IA/g; n=1).

radiopeptide	[ $^{177}\text{Lu}$ ]Lu-DOTA-MGS5	[ $^{177}\text{Lu}$ ]Lu-1	[ $^{177}\text{Lu}$ ]Lu-2
<b>blood</b>	0.09	0.03	0.02
<b>lung</b>	0.08	0.06	0.20
<b>heart</b>	0.08	0.05	0.04
<b>femur</b>	0.04	0.18	0.09
<b>muscle</b>	0.03	0.02	0.04
<b>spleen</b>	0.16	1.13	0.70
<b>intestine</b>	0.79	0.17	0.45
<b>liver</b>	0.54	2.86	1.13
<b>kidneys</b>	2.95	9.21	1.47
<b>stomach</b>	0.09	0.06	0.09
<b>pancreas</b>	0.11	0.05	0.05
<b>A431-CCK2R</b>	0.54	0.45	0.39
<b>A431-mock</b>	0.34	0.12	0.16



**Figure S3.** Uptake of  $[^{177}\text{Lu}]$ Lu-2 in different tissues dissected from A431-CCK2R xenografted BALB/c nude mice for up to 7 days after injection ( $n=5$ ).

**Table S3.** Uptake values of [<sup>177</sup>Lu]Lu-2 in A431-CCK2R tumor xenograft for up to 7 days after injection (n=5).

Timepoint p.i.	1 h	24 h	3 days	7 days
	[% IA/g]	[% IA/g]	[% IA/g]	[% IA/g]
<b>blood</b>	1.45±0.30	0.01±0.00	0.00±0.00	0.01±0.00
<b>lung</b>	4.33±0.87	0.09±0.02	0.06±0.01	0.02±0.01
<b>heart</b>	0.62±0.12	0.05±0.01	0.02±0.00	0.02±0.00
<b>femur</b>	0.23±0.05	0.05±0.01	0.03±0.01	0.04±0.02
<b>muscle</b>	0.22±0.05	0.03±0.00	0.01±0.00	0.01±0.01
<b>spleen</b>	0.54±0.08	0.19±0.03	0.13±0.02	0.09±0.04
<b>intestine</b>	1.00±0.34	0.16±0.02	0.08±0.00	0.03±0.00
<b>liver</b>	0.95±0.12	0.38±0.08	0.18±0.01	0.06±0.01
<b>kidneys</b>	2.84±0.42	1.32±0.23	0.72±0.10	0.31±0.03
<b>stomach</b>	5.43±1.05	3.66±0.38	2.28±0.33	0.88±0.12
<b>pancreas</b>	0.85±0.14	0.41±0.08	0.28±0.04	0.16±0.04
<b>A431-CCK2R</b>	56.29±9.14	33.61±2.95	12.52±0.96	1.23±0.53